Arcus Biosciences Inc
Arcus Biosciences Inc (RCUS) Unusual Options Activity Today
RCUS options volume power reached 0.04x on the previous trading day. The highest reading was on the $30 CALL expiring 2026-12-18.
Read more
Checking RCUS unusual options activity helps you spot when traders are making outsized bets on Arcus Biosciences Inc before the broader market catches on. Arcus Biosciences Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor RCUS unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching RCUS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking RCUS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and RCUS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.
It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Catalysts rarely arrive without a footprint, and RCUS unusual options activity is often where that footprint shows up first. Our scanner tracks Arcus Biosciences Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at RCUS unusual options volume on the call side or chasing put sweeps, Arcus Biosciences Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 30.00 | 0.05 | 3.60 | 1.83 | 158% | 10 | 370 | 2.70% |
| 20.00 | 3.20 | 7.00 | 5.10 | 59% | 12 | 5,338 | 0.22% |
| 2.50 | 20.00 | 24.80 | 22.40 | 88% | 0 | 0 | — |
| 5.00 | 17.50 | 22.40 | 19.95 | 91% | 0 | 0 | — |
| 7.50 | 15.00 | 19.90 | 17.45 | 49% | 0 | 0 | — |
| 2.50 | — | 0.05 | 0.05 | 499% | 0 | 0 | — |
| 5.00 | — | 5.00 | 5.00 | 1,000% | 0 | 4 | 0.00% |
| 7.50 | — | 5.00 | 5.00 | 1,000% | 0 | 0 | — |
| 10.00 | — | 5.00 | 5.00 | 878% | 0 | 36 | 0.00% |
| 12.50 | — | 5.00 | 5.00 | 697% | 0 | 0 | — |
As of September 28, 2026
Spot unusual options activity before it moves
Track RCUS options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→